Baseline patient and disease characteristics
| Characteristic . | N = 21 . |
|---|---|
| Age, median (range), y | 66 (51-85) |
| Male, n (%) | 17 (81) |
| White race, n (%) | 19 (91) |
| ECOG PS, n (%) | |
| 0 | 11 (52) |
| 1 | 9 (43) |
| 2 | 1 (5) |
| Bulky lymph nodes, n (%) | |
| >5 cm | 7 (33) |
| ≥10 cm | 1 (5) |
| BM involvement, n (%) | 15 (71) |
| Extranodal disease, n (%) | 13 (62) |
| Ann Arbor stage IV disease, n (%) | 19 (90) |
| Simplified MIPI score, n (%)∗ | |
| Low risk (0-3) | 5 (24) |
| Intermediate risk (4-5) | 11 (52) |
| High risk (6-11) | 4 (19) |
| Missing | 1 (5) |
| Blastoid/pleomorphic MCL, n (%) | 1 (5) |
| Ki-67 proliferation index, n (%)† | |
| <30% | 10 (48) |
| ≥30% | 10 (48) |
| Missing | 1 (5) |
| Characteristic . | N = 21 . |
|---|---|
| Age, median (range), y | 66 (51-85) |
| Male, n (%) | 17 (81) |
| White race, n (%) | 19 (91) |
| ECOG PS, n (%) | |
| 0 | 11 (52) |
| 1 | 9 (43) |
| 2 | 1 (5) |
| Bulky lymph nodes, n (%) | |
| >5 cm | 7 (33) |
| ≥10 cm | 1 (5) |
| BM involvement, n (%) | 15 (71) |
| Extranodal disease, n (%) | 13 (62) |
| Ann Arbor stage IV disease, n (%) | 19 (90) |
| Simplified MIPI score, n (%)∗ | |
| Low risk (0-3) | 5 (24) |
| Intermediate risk (4-5) | 11 (52) |
| High risk (6-11) | 4 (19) |
| Missing | 1 (5) |
| Blastoid/pleomorphic MCL, n (%) | 1 (5) |
| Ki-67 proliferation index, n (%)† | |
| <30% | 10 (48) |
| ≥30% | 10 (48) |
| Missing | 1 (5) |